Citius Oncology, Inc. (NASDAQ:CTOR) Shares Shorted: Short Interest Down 43.1% in September

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 289,717 shares, a decline of 43.1% from the September 15th total of 509,543 shares. Based on an average trading volume of 129,388 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Investors Weigh In On Citius Oncology

An institutional investor recently raised its position in Citius Oncology stock. Bank of America Corp DE lifted its stake in shares of Citius Oncology, Inc. (NASDAQ:CTOR) by 1,792,030.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,835,160 shares of the company’s stock after buying an additional 3,834,946 shares during the quarter. Bank of America Corp DE owned 4.34% of Citius Oncology worth $2,374,000 as of its most recent filing with the SEC. Institutional investors own 70.52% of the company’s stock.

Citius Oncology Trading Down 2.5%

Shares of CTOR traded down $0.02 on Thursday, hitting $0.76. 9,604 shares of the stock traded hands, compared to its average volume of 153,769. The firm has a market capitalization of $71.04 million, a P/E ratio of -1.61 and a beta of 3.39. The company has a quick ratio of 0.34, a current ratio of 0.73 and a debt-to-equity ratio of 0.25. Citius Oncology has a 1 year low of $0.49 and a 1 year high of $2.25. The stock’s 50 day moving average is $0.87 and its two-hundred day moving average is $0.79.

Citius Oncology (NASDAQ:CTOR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $1.49 million during the quarter, compared to the consensus estimate of $2.50 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Citius Oncology Company Profile

Citius Oncology, Inc (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and related serious diseases. The company was established as an oncology-focused subsidiary of Citius Pharmaceuticals and became a separately traded public company following a business combination.

Citius Oncology’s lead product is LYMPHIR (denileukin diftitox-cxdl), a targeted immunotherapy approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.